Radiobiology - Understanding the body's response to radiopharmaceuticals

Targeted radionuclide therapies are undergoing rapid growth as next-generation radiotherapeutics for multiple cancers. Targeted alpha-therapeutics (TATs) in particular are highly potent and outperform current clinical options, representing an opportunity to produce a step change in patient outcomes. Despite international research focus on developing TATs, there remains significant knowledge gaps in understanding associated biological and immunological responses which have key impacts on subsequent efficacy. I have multiple ongoing projects working to addresses this by investigating the interplay between TAT and associated localized cellular, inflammation and immune responses. These projects all fall within my research theme of radiobiology and range from assays in molecular and cellular biology, through to preclinical efficacy and molecular imaging studies to probe all aspects of this research question.